Pemetrexed is a new-generation antifolate drug, now widely used in patients with non-small cell lung cancer (NSCLC). We report a case of pemetrexed-induced interstitial pneumonitis, and review the literature of eight previously reported cases. As pemetrexed is now a widely used chemotherapeutic agent, it is important to be aware of rare adverse events related to its administration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649774 | PMC |
| http://dx.doi.org/10.14740/wjon845w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pseudocellulitis in the Setting of Pemetrexed Treatment for Non-Small Cell Lung Cancer.
J Cutan Pathol
January 2025
Division of Dermatology, The University of Texas at Austin, Dell Medical School, Austin, Texas, USA.
Pemetrexed is a chemotherapeutic, antimetabolite agent that has been used in oncology to treat diseases such as metastatic non-small cell lung cancer and unresectable malignant pleural mesothelioma. Pemetrexed use may result in pseudocellulitis, which presents as poorly demarcated patches or plaques with erythema, edema, warmth, and tenderness. These lesions can present unilaterally or bilaterally on the lower extremities.
View Article and Find Full Text PDFRenal Immune-related Adverse Event of Pembrolizumab Masked by Pemetrexed.
Intern Med
January 2024
Department of Nephrology, Chubu Rosai Hospital, Japan.
Article Synopsis
- * A renal biopsy revealed damage likely caused by pemetrexed, leading to its withdrawal, but her kidney function continued to decline.
- * A second biopsy indicated severe acute kidney inflammation from pembrolizumab, highlighting the need to be cautious about kidney toxicity when combining immunotherapies with chemotherapy.
Immunoglobulins as a treatment modality for corticosteroid-refractory pemetrexed-induced interstitial lung disease, case report.
Respir Med Res
June 2023
Service de Pneumologie, Centre Hospitalier Universitaire de Besançon, 3 Boulevard Fleming, Besançon 25030 CEDEX, France; UMR 1098, Université de Franche-Comté, Besançon, France.
Pemetrexed-induced Sweet Syndrome: First case report in the medical literature.
J Oncol Pharm Pract
July 2021
Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey.
Introduction: Sweet Syndrome, also known as acute febrile neutrophilic dermatosis, is a rare inflammatory disease characterized by the sudden emergence of painful, edematous, and erythematous papules, plaques, or nodules on the skin, which usually fully responsive to systemic corticosteroids. Skin lesions are often accompanied by fever and leukocytosis. Here we present a case of Sweet Syndrome caused by pemetrexed in metastatic lung adenocarcinoma.
View Article and Find Full Text PDFPemetrexed-induced Interstitial Lung Disease Mimicking Hypersensitivity Pneumonia: A Pathologically Proven Case.
Intern Med
September 2019
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
We herein report a 45-year-old woman with lung adenocarcinoma stage IV (cT4N3M1a). She was treated with pemetrexed (PEM) monotherapy following four cycles of first-line treatment with carboplatin, paclitaxel, and veliparib. After three cycles of PEM treatment, she presented with dyspnea, and chest computed tomography showed diffuse ground-glass attenuation (GGA), suggesting hypersensitivity pneumonia (HP).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!